Year: 2018
BerGenBio Presents Key Results from PhII Programme with Selective AXL Inhibitor Bemcentinib at DNB’s 9th Annual Nordic Healthcare Conference
December 12, 2018
Bemcentinib proof of concept clinical data as monotherapy and in combination confirms focus on lung…
Read More
BerGenBio reports 43% response rate with bemcentinib monotherapy in AXL positive R/R AML/MDS patients at ASH
December 3, 2018
43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6…
Read More
BerGenBio appoints cancer drug development specialist Alan Barge MD as interim Chief Medical Officer
November 26, 2018
Further senior organisational changes made in preparation for advancing bemcentinib into the next stage of…
Read More
BerGenBio ASA: Results for the Third Quarter 2018
November 13, 2018
Phase II data in NSCLC with bemcentinib/KEYTRUDA combination: First stage of trial in previously treated…
Read More
BerGenBio reports ~80% improvement in PFS of AXL-positive vs AXL-negative NSCLC patients in bemcentinib + KEYTRUDA PhII combination trial
November 6, 2018
Late breaking abstract at SITC: Analysis of first stage of phase II trial with selective…
Read More
BerGenBio to present late-breaking abstract on Phase II trial of bemcentinib in combination with KEYTRUDA® in advanced NSCLC at SITC
November 2, 2018
Combination of selective AXL inhibitor bemcentinib and KEYTRUDA® featured in late breaking abstract at leading…
Read More
